Ondine Announces Findings in Photodisinfection Treatment of MRSA to be Presented at the Society for General Microbiology's 162nd Meeting in Scotland



    VANCOUVER, March 6 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP; the "Company"), a medical technology company developing
photodisinfection based products, today announced that results from two
research studies from its Methicillin Resistant Staphylococcus aureus (MRSA)
program will be presented at the Society for General Microbiology's 162nd
Meeting held March 31 - April 3, 2008 in Edinburgh, Scotland. The studies
provide detailed results of Ondine's photodisinfection system in the
eradication of Staphylococcus aureus, a bacterium which secretes potent cell
wall-bound virulence factors that enhance host tissue destruction.
Staphylococcus aureus has become resistant to many antibiotics including in
some cases to vancomycin, often considered the antibiotic of last resort.
These studies were conducted under Professor Michael Wilson, Head of
Microbiology at UCL's Eastman Dental Institute as part of an ongoing research
collaboration between Ondine Biopharma and the University College London
(UCL).
    "MRSA is known to produce toxins that are responsible for destroying cell
tissue. These toxins continue to destroy the tissue even after antibiotics
have killed the organism," stated Professor Michael Wilson. "Ondine's
photodisinfection technology kills both the bacteria and substantially
inactivates these toxins, something that none of the antibiotics used to kill
MRSA today are able to accomplish. This dual-mode approach also does not
contribute to bacterial resistance, another critical advantage of Ondine's
photodisinfection system."
    "The attention given to this work by the scientific and medical
communities is a testament to the high level of interest in developing
non-antibiotic treatments to help curb the spread of MRSA," said Dr. Cale
Street, Ondine's Director of Research. "These and other studies using Ondine's
technology at UCL are at the leading edge of scientific progress in the field
of photodisinfection, and are being translated into therapies for MRSA nasal
decolonization and the treatment of wound and other topical infections."

    The following two abstracts are scheduled to be presented:

    Presentation Number MI-03:
    "Lethal photosensitization of Staphylococcus aureus using a tin chlorin
    e6-gold Nnanoparticle."
    Dekker, L., Gil-Tomas, J., Narband, N., Nair, N., Parkin., Street, C.,
    and Wilson, M.

    Presentation Number MI-04:
    "Inactivation of staphylococcal virulence factors using light-activated
    antimicrobial agents."
    Tubby, S., Wilson, M., Street, C., and Nair, S.

    Additional information on these presentations and the Society for General
    Microbiology can be found at http://www.sgm.ac.uk/default.cfm.

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com.

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release.





For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com; Irma
Gomez-Dib, Media & Investors Relations, FD International, (212) 850-5761,
Irma.gomez-dib@fd.com; Canaccord Adams Ltd, Nominated Adviser & Broker, Neil
Johnson, Ryan Gaffney, +4420 7050 6500

Organization Profile

ONDINE BIOPHARMA CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890